Curis to Release Third Quarter 2021 Financial Results and Hold Conference Call on November 9, 2021

Rhea-AI Summary

Curis, Inc. (NASDAQ: CRIS) is set to release its third quarter 2021 financial results on November 9, 2021, after market close. Management will host a conference call at 4:30 PM ET to discuss the results. Curis focuses on innovative cancer therapeutics, holding exclusive licenses for several small molecule antagonists and conducting clinical trials for drugs like CA-4948 in non-Hodgkin's lymphoma and acute myeloid leukemia. Key collaborations include partnerships with Aurigene and Genentech for drug development and commercialization.

Positive

• Curis is advancing its oncology pipeline with drugs in clinical trials, including CA-4948 for non-Hodgkin's lymphoma and acute myeloid leukemia.
• The company has received Orphan Drug Designation for CA-4948 from the FDA.

Negative

• None.

LEXINGTON, Mass., Nov. 2, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter 2021 financial results on Tuesday, November 9, 2021, after the close of U.S. markets. Management will host a conference call on the same day at 4:30 pm ET.

To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 4:30 pm ET. The conference call can also be accessed on the Curis website at www.curis.com in the 'Investors' section. A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.

About Curis, Inc.

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1/2 trial in patients with non-Hodgkin's lymphoma both as a monotherapy and in combination with BTK inhibitor ibrutinib. Curis is also evaluating CA-4948 in a Phase 1/2 trial in patients with acute myeloid leukemia and myelodysplastic syndromes, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1 trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge^® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-release-third-quarter-2021-financial-results-and-hold-conference-call-on-november-9-2021-301414597.html

SOURCE Curis, Inc.

FAQ

When will Curis release its third quarter 2021 financial results?

Curis will release its third quarter 2021 financial results on November 9, 2021, after the close of U.S. markets.

What time is the Curis conference call on November 9, 2021?

The Curis conference call will take place at 4:30 PM ET on November 9, 2021.

What is the focus of Curis, Inc.?

Curis is focused on developing innovative therapeutics for the treatment of cancer.

Which drugs are Curis currently testing?

Curis is testing CA-4948 for non-Hodgkin's lymphoma and acute myeloid leukemia, as well as CI-8993 for solid tumors.

Who are Curis's partners in drug development?

Curis has partnerships with Aurigene and Genentech, focusing on various oncology therapies.